Announcement on Approval for Marketing of Betamethasone API by Brazilian Health Regulatory Agency
Securities code: 600488 Securities abbreviation: Jinyao Pharmaceutical Number: 2026-040
Jinyao Pharmaceutical Co., Ltd.
Announcement on the approval of betamethasone API for marketing by the Brazilian Health Supervision Bureau
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Recently, Jinyao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") received an approval notice for betamethasone API (hereinafter referred to as the "drug") issued by the Brazilian Health Supervision Agency (hereinafter referred to as "Brazil ANVISA"). The relevant information is now announced as follows:
1. Basic information about drugs
Drug name: Betamethasone/Betamethasone
Drug manufacturer/holder: Jinyao Pharmaceutical Co., Ltd.
Production address: No. 19, Xinye 9th Street, West District, Tianjin Development Zone
4.Certificate number: 25351255134202310 Rev.001
Issuing agency: Brazilian Health Supervision Agency (ANVISA)
Validity period: long-term
2. Other related information about drugs
Betamethasone is suitable for postural hypotension and allergic and autoimmune inflammatory diseases caused by low renin and low aldosterone syndrome and autonomic neuropathy. It is now mostly used for active rheumatism, rheumatoid arthritis, lupus erythematosus, severe bronchial asthma, severe dermatitis, acute leukemia, etc. It is also used for the comprehensive treatment of certain infections. The company submitted a betamethasone API registration application to Brazil's ANVISA in April 2023, and it was approved recently.
According to the IQVIA database, the global market sales of betamethasone preparations in 2024 and 2025 will be US$816 million and US$835 million respectively.
3. Impact on listed companies and risk warnings
The company's betamethasone API has been approved by Brazil's ANVISA, marking that the company can meet regulatory requirements.
1/2
The combined preparations customer demand will have a positive impact on the company's expansion into the Brazilian market and improvement of performance. Since the sales time, market scale, and subsequent expansion progress of this drug in foreign markets are uncertain, and the drug export business is easily affected by factors such as changes in the foreign market environment and exchange rate fluctuations, investors are kindly requested to invest rationally and pay attention to guarding against investment risks.
Announcement is hereby made.
Board of Directors of Jinyao Pharmaceutical Co., Ltd.
July 7, 2026
2/2